<SEC-DOCUMENT>0001171843-21-000737.txt : 20210204
<SEC-HEADER>0001171843-21-000737.hdr.sgml : 20210204
<ACCEPTANCE-DATETIME>20210204085940
ACCESSION NUMBER:		0001171843-21-000737
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210203
FILED AS OF DATE:		20210204
DATE AS OF CHANGE:		20210204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		21589000

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_020421.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong>Date of report:&#160;</strong><strong>For the month of February 2021</strong></p><p style="text-align: center;"><strong>Commission File Number: 001-39084</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Innate Pharma S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Innate Pharma S.A.<br />117 Avenue de Luminy&#8212;BP 30191<br />13009 Marseille, France <br />+ 33 (0) 4 30 30 30 &#160;</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p>
 <p align="center"><font style="font-size:10pt;"><strong>EXHIBIT INDEX</strong></font></p>   <p align="center" style="text-align: center;"><font style="font-size:10pt;">&#160;</font></p>  <table style="border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Exhibit</u></strong></font></td><td class="hugin"><font style="font-size:10pt;">&#160; &#160;&#160;</font></td><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Description</u></strong></font></td></tr><tr><td class="hugin">&#160;</td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td></tr><tr><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">Press Release dated February 3, 2021</a></font> </font></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td>&#160;</td><td>&#160;</td><td style="text-transform: uppercase;" colspan="2"><strong>Innate Pharma S.A.</strong></td></tr><tr valign="top"><td style="width: 47%;">&#160;</td><td style="width: 6%;">&#160;</td><td style="text-align: center; width: 10%;">&#160;</td><td style="text-align: center; width: 84%;">&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr><tr valign="top"><td>Date: February 3, 2021</td><td>&#160;</td><td>By:</td><td style="border-bottom: black 1pt solid;">/s/ Laure-H&#233;l&#232;ne Mercier&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Name:&#160;&#160;&#160;&#160;&#160;</td><td>Laure-H&#233;l&#232;ne Mercier</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Title:</td><td>Chief Financial Officer</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas</strong></font></p><p style="text-align: center;"><strong>Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021</strong></p><p>
 <p align="justify">MARSEILLE, France, Feb.  03, 2021  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH &#8211; ISIN: FR0010331421; Nasdaq: IPHA) (&#8220;<strong>Innate</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.<br ></p>  <p align="justify">The event will feature presentations from the Company&#8217;s executive leadership team, as well as the following KOLs:</p>  <ul type="disc"><li style="text-align:justify;"><strong>Pierluigi Porcu, M.D.</strong>, Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate&#8217;s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and S&#233;zary syndrome; and</li><li style="text-align:justify;"><strong>Olivier Hermine, M.D.</strong>, Professor of Hematology at the University of Paris Descartes and Director, Division of Adult Hematology at H&#244;pital Universitaire Necker Enfants Malades, Member of the Acad&#233;mie des Sciences, Member of the Lymphoma Study Association (LYSA), France</li></ul>  <p align="justify">Presenters will provide an overview of the treatment landscape and prevalence of the lacutamab target, KIR3DL2, across subtypes of T-cell lymphoma. They will also highlight the potential impact of lacutamab in current and upcoming clinical programs in cutaneous and peripheral T-cell lymphomas.</p>  <p align="justify"><strong><u>Details for the Virtual Event</u></strong></p>  <p align="center">The live webcast of the event will be available at the following link: <br >https://edge.media-server.com/mmc/p/yztsebvs</p>  <p align="justify">A telephone number will also be made available. Participants may register in advance of the event at http://emea.directeventreg.com/registration/2284358. Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.</p>  <p align="justify">A replay of the webcast will be archived on Innate&#8217;s website for 90 days following the event.</p>  <p align="justify">This information can also be found in the Investors section of the Innate website, www.innate-pharma.com.</p>  <p align="justify"><strong>About Lacutamab:</strong><br >Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.&#160;</p>  <p align="justify">KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, S&#233;zary syndrome. It is expressed by up to 50% of patients with peripheral t-cell lymphoma (PTCL). It has a restricted expression on normal tissues.</p>  <p align="justify"><strong>About Innate Pharma:</strong></p>  <p align="justify">Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.</p>  <p align="justify">Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.</p>  <p align="justify">Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.</p>  <p align="justify">Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>  <p align="justify">Learn more about Innate Pharma at www.innate-pharma.com&#160;</p>  <p align="justify"><strong>Information about Innate Pharma shares:</strong></p> <table align="center" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:15%; width:15%; min-width:15%;;text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>ISIN code</strong><br ><strong>Ticker code</strong><br ><strong>LEI</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ;  vertical-align: middle; vertical-align: top ; ">FR0010331421<br >Euronext: IPH Nasdaq: IPHA<br >9695002Y8420ZB8HJE29</td></tr></table> <p align="justify"><strong>Disclaimer on forward-looking information and risk factors: </strong></p>  <p align="justify">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.</p>  <p align="justify">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</p>  <p align="justify"><strong>For additional information, please contact:</strong></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:30%; width:30%; min-width:30%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong><u>Investors</u></strong><br ><br ><strong>Innate Pharma</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br >Tel.: +33 (0)4 30 30 30 30<br >investors@innate-pharma.com<br ></td><td style="max-width:70%; width:70%; min-width:70%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong><u>Media</u></strong><br ><br ><strong>Innate Pharma </strong><br >Tracy Rossin (Global/US)<br >Tel.: +1 240 801 0076<br >Tracy.Rossin@innate-pharma.com<br ><br ><strong>ATCG Press </strong><br >Marie Puvieux (France)<br >Tel.: +33 (0)9 81 87 46 72<br >innate-pharma@atcg-partners.com</td></tr></table></p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
